ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1572

Associations Between the Gut Microbiota, Ultra-Processed Food Intake, and Gastrointestinal Tract Symptoms in Patients with Systemic Sclerosis

Ju Young Lee1, Swapna Joshi2, Arissa Young3, Jen Labus2, Zsuzsanna McMahan4, Ezinne Aja2, Jonathan Jacobs2 and Elizabeth Volkmann5, 1David Geffen School of Medicine, UCLA, Los Angeles, CA, 2UCLA, Los Angeles, 3UCLA, Los Angeles, CA, 4UTHealth Houston Division of Rheumatology, Houston, TX, 5University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles

Meeting: ACR Convergence 2024

Keywords: diet, microbiome, Scleroderma, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Alterations in the gastrointestinal (GI) microbiome (i.e., dysbiosis) are a feature of systemic sclerosis (SSc) [1]. Diet is a known modifier of the GI microbiome, and ultra-processed food (UPF) consumption, specifically, has been associated with adverse changes in GI microbial composition [2]. This study aimed to determine whether UPF consumption affects the GI microbiota and symptoms in patients with SSc.

Methods: Adult SSc patients provided stool samples and completed both the Diet History Questionnaire II (DHQ-2) and the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument (GIT 2.0). Shotgun metagenomics were performed using the Illumina NovaSeq 6000 with a target depth of 20 million 150×2 sequences per sample. Shotgun reads were inputted into MetaPh1An2 for taxonomic identification of species for compositional analysis, and samples were filtered to retain species with at least 25% non-zero counts. UPF items (N=54) on the DHQ-2 were identified using the NOVA scale of food classification [3]. UPF intake was calculated as a continuous variable by gram-per-week consumption according to patient reported frequency. General linear models were created to identify differentially abundant species based on UPF consumption and to evaluate the relationship between UPF consumption and GI symptoms as measured by the GIT 2.0. These models adjusted for body mass index (BMI), current proton pump inhibitor (PPI) use, current probiotic use, current or prior immunomodulatory therapy, and presence of small intestinal bacterial overgrowth (SIBO). The False Discovery Rate (FDR) was used to correct for multiple hypothesis testing.

Results: Of the 65 total SSc patients included, 59 were female (90.7%). The mean age was 53.25 years (SD=12.84), and the mean BMI was 25.7 (SD=4.88). The median UPF consumption was 2394.5 grams/week with a range of 174.5-46978.2 grams/week. Among 257 species analyzed, the abundance of 10 bacterial species was significantly altered based on UPF consumption in study participants. After adjusting for the aforementioned covariates, 5 bacterial species were significantly associated with UPF consumption [Table 1], including Limosilactobacillus fermentum (Std-beta 0.32; p< 0.01) [Figure 1A] and Faecalicatena fissicatena (Std-beta -0.35; p< 0.01) [Figure 1B]. Increased UPF intake was significantly associated with GI symptoms in the multivariable model (Std-beta 0.34; p< 0.01) [Figure 2].

Conclusion: SSc patients reporting a higher UPF consumption demonstrated alterations in GI microbial composition as well as increased GI symptoms, even after adjusting for factors known to affect the microbiota of patients with SSc. Future studies are needed to determine whether interventions aimed at lowering UPF consumption may improve GI outcomes for patients with SSc.

1. Andréasson K, et al. ACR Open Rheumatol 2022;4(5):417-425.  
2. Chassaing B, et al. Gut 2017;66(8):1414-1427  
3. Monteiro CA, et al. Public Health Nutr 2018;21(1):5-17.

Supporting image 1

Supporting image 2

Figure 1. Relationship between (A) Limosilactobacillus fermentum species abundance, (B) Faecalicatena fissicatena species abundance (y-axis) and UPF consumption (x-axis, grams/week) based on generalized linear model estimates, adjusting for BMI, PPI use, probiotic use, immunomodulatory use, and presence of SIBO.

Supporting image 3

Figure 2. Relationship between predicted GIT 2.0 score (y-axis) and UPF consumption (x-axis, grams/week) based on generalized linear model estimates, adjusting for BMI, PPI use, probiotic use, immunomodulatory use, and presence of SIBO.


Disclosures: J. Lee: None; S. Joshi: None; A. Young: None; J. Labus: None; Z. McMahan: Boehringer-Ingelheim, 2; E. Aja: None; J. Jacobs: None; E. Volkmann: AbbVie, 2, Boehringer-Ingelheim, 2, 5, 6, GSK, 2, 5, Horizon, 5, Kadmon, 5, Prometheus, 5.

To cite this abstract in AMA style:

Lee J, Joshi S, Young A, Labus J, McMahan Z, Aja E, Jacobs J, Volkmann E. Associations Between the Gut Microbiota, Ultra-Processed Food Intake, and Gastrointestinal Tract Symptoms in Patients with Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/associations-between-the-gut-microbiota-ultra-processed-food-intake-and-gastrointestinal-tract-symptoms-in-patients-with-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/associations-between-the-gut-microbiota-ultra-processed-food-intake-and-gastrointestinal-tract-symptoms-in-patients-with-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology